Shashi B Singh, Thomas J Werner, William Y Raynor, Abass Alavi, Mona-Elisabeth Revheim, Sambhawana Bhandari, Sadikshya Bhandari, Samikshya Bhandari, Rajshree Singh, Soren Hess
Journal: Annals of nuclear medicine 2024;38(3):165-175
PMID: 38277115
Rheumatoid Arthritis (RA) is a systemic inflammatory disorder that commonly presents with polyarthritis but can have multisystemic involvement and complications, leading to increased morbidity and mortality. The diagnosis of RA continues to be challenging due to its varied clinical presentations. In this review article, we aim to determine the potential of PET/CT to assist in the diagnosis of RA and its complications, evaluate the therapeutic response to treatment, and predict RA remission. PET/CT has increasingly been used in the last decade to diagnose, monitor treatment response, predict remissions, and diagnose subclinical complications in RA. PET imaging with [F]-fluorodeoxyglucose ([F]-FDG) is the most commonly applied radiotracer in RA, but other tracers are also being studied. PET/CT with [F]-FDG, [F]-NaF, and other tracers might lead to early identification of RA and timely evidence-based clinical management, decreasing morbidity and mortality. Although PET/CT has been evolving as a promising tool for evaluating and managing RA, more evidence is required before incorporating PET/CT in the standard clinical management of RA.
© 2024. The Author(s).
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.